1. Treating CD30-Expressing Cutaneous T-Cell Lymphoma

2. Introduction to CD30

3. Evaluation of CD30 Expression in Lymphomas

4. Pathology Report of CD30 Expression

5. Testing Methodology for CD30 Expression

6. CD30 Staining in pcALCL vs MF/SS

7. Issues Related to CD30-Negative Expression

8. CD30 Testing in Other Lymphoma Conditions

9. Therapeutic Approach for Patients With CD30-Positive MF/SS

10. Long-Term Management of Patients Receiving Systemic Therapies

11. ALCANZA Trial Study Design

12. ALCANZA Trial Efficacy

13. ALCANZA Trial Safety Profile

14. Treatment Strategy With BV

15. Factors to Consider in Optimizing Course of Treatment

16. MAVORIC Trial Study Design

17. MAVORIC Trial Patient Characteristics and Efficacy

18. ALCANZA vs MAVORIC

19. MAVORIC Trial Safety Profile

20. Potential Increase in GVHD in Patients With CTCL After Mogamulizumab Treatment

21. Ongoing Clinical Trials

22. Key Takeaways

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)